|
Assessment of Rationale Use of Anti-Osteoporosis Drugs at a University Hospital |
|---|---|
| รหัสดีโอไอ | |
| Creator | Cheardchai Soontornpas |
| Title | Assessment of Rationale Use of Anti-Osteoporosis Drugs at a University Hospital |
| Contributor | Ratchadaporn Soontornpas |
| Publisher | Faculty of Pharmaceutical Sciences KKU MSU UBU |
| Publication Year | 2561 |
| Journal Title | Isan Journal of Pharmaceutical Sciences |
| Journal Vol. | 14 |
| Journal No. | 2 |
| Page no. | 47-55 |
| Keyword | non-essential drug, osteoporosis, evaluation of rationale drug use |
| URL Website | https://tci-thaijo.org/index.php/IJPS |
| Website title | Isan Journal ofPharmaceutical Sciences, IJPS |
| ISSN | 19050852 |
| Abstract | Prescribing of anti-osteoporosis drugs for patients under the civil servant medical benefit scheme (CSMBS) in public hospitals must be followed the recommendation on drug use indicator for high cost non-essential drug belonged to the Subcommittee for Determining the Practice Guideline, Drug Use Indicator, Diagnosis and Medical Treatment 2013 to encourage the rational drug use and control drug cost. This study aimed to assess the rationality of non-essential drug (NED) prescribing in anti-osteoporosis group. Methods: This retrospective study was studied by gathering the information about the indication for prescribing anti-osteoporosis drugs from the electronic database and from the medical records of the out-patients with CSMBS at Srinagarind Hospital between August 1st and September 30th, 2014. Data were analyzed by descriptive statistics. Results: There were 463 patients recruited into the study. Patients were mainly female (94.2%) and aged over 65 years (70.2%). The top three most prescribed drugs were alendronate plus cholecalciferol, followed by risedronate and ibandronate (41.7, 22.9 and 11.0%, respectively). Prescribing was rationale and irrational in 56.4% and 25.7%, respectively; meanwhile, the rationality could not be assessed in 17.9% because of data lacking in the outpatient medical record. Conclusions: Fifty-six percent of prescribing of anti-osteoporosis drugs were rationale according to the recommendation on indication for high cost NED. |
